US04522R2004 - ADR
ASLAN PHARMACEUTICALS LT-ADR
NASDAQ:ASLN (5/9/2024, 1:19:21 PM)
0.42
+0.02 (+4.35%)
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. The company employs 34 full-time employees The company went IPO on 2017-06-01. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
ASLAN PHARMACEUTICALS LT-ADR
83 Clemenceau Avenue, #12-03 UE Square
Singapore 239920
P: 6562224235
CEO: Carl Firth
Employees: 34
Website: http://aslanpharma.com/zh/
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ASLAN Pharma (NASDAQ:ASLN) just reported results for the first quarter of 2024....
ASLN stock results show that ASLAN Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD)...
New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the...
Here you can normally see the latest stock twits on ASLN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: